Question 1

What is Brigatinib?

Accepted Answer

Brigatinib belongs to a class of medications called kinase inhibitors. It works by interfering with the activity of specific proteins that signal cancer cells to multiply and spread.

By blocking these signals, the medication helps to slow or stop the growth of cancer cells.

Question 2

What is Brigatinib used for?

Accepted Answer

Brigatinib is used to treat non-small cell lung cancer .

Question 3

How does Brigatinib work?

Accepted Answer

Mechanism of Action

Brigatinib belongs to a class of drugs called tyrosine kinase inhibitors. It is designed to target and block the activity of certain abnormal proteins in the body, most notably the anaplastic lymphoma kinase (ALK) protein.

In some types of non-small cell lung cancer, the ALK gene becomes altered, causing the body to produce an overactive ALK protein. This abnormal protein sends constant signals to cancer cells, telling them to divide and multiply rapidly. Brigatinib works by:

Binding to the ALK protein: By attaching to the protein, the drug prevents it from sending growth signals.

Inhibiting other targets: It also blocks other proteins, such as ROS1, which can contribute to cancer progression.

Slowing tumor growth: By cutting off these signaling pathways, the medication helps slow down or stop the spread of the cancer.

Because brigatinib targets specific proteins found primarily on or in cancer cells, it is considered a targeted therapy. This approach aims to interfere with the specific molecules involved in tumor growth rather than affecting all rapidly dividing cells in the body.

Question 4

What are the brand names for Brigatinib?

Accepted Answer

Brigatinib is sold under the brand name Alunbrig .

Question 5

What are the active ingredients in Brigatinib?

Accepted Answer

The active ingredient in Brigatinib is brigatinib .

Question 6

What are the side effects of Brigatinib?

Accepted Answer

Common side effects of Brigatinib may include:

Nausea

Diarrhea

Fatigue

and others.

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Brigatinib?

Accepted Answer

Brigatinib belongs to the ALK inhibitor drug class.

Question 8

What is the dosage of Brigatinib and how do I take it?

Accepted Answer

How to Take Brigatinib

Brigatinib is taken by mouth once a day. It can be taken with or without food. It is important to take the medication at approximately the same time every day to maintain a consistent level in your body.

The standard treatment schedule typically begins with a lower dose for the first seven days. If the medication is tolerated well, the dose is then increased for the remainder of the treatment. Your healthcare provider will determine the appropriate schedule for you.

Swallow tablets whole; do not crush, chew, or break them.

Avoid grapefruit products while taking this medication, as they can increase the amount of the drug in your bloodstream.

Missed Doses

If you miss a dose or if you vomit after taking a dose, do not take an extra tablet. Skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at once.

Question 9

Is Brigatinib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy and Contraception

Brigatinib may cause birth defects or the death of an unborn baby. Healthcare providers typically require a pregnancy test before starting treatment to confirm that a patient is not pregnant. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks with your healthcare team.

Effective birth control is required for patients of reproductive potential during and after treatment:

Females: Use effective birth control during treatment and for at least 4 months after the final dose. Brigatinib may interact with hormonal contraceptives (such as pills, patches, or injections), making them less effective. Non-hormonal birth control methods are generally recommended.

Males: Men with female partners who are able to become pregnant should use effective birth control during treatment and for at least 3 months after the final dose.

Breastfeeding

It is not known whether brigatinib passes into breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least 1 week after the last dose of the medication.

Question 10

What forms and strengths does Brigatinib come in?

Accepted Answer

Dosage Forms

Brigatinib is available as a tablet to be taken by mouth. It is typically administered once daily, with or without food.

The tablets are intended to be swallowed whole. They should not be crushed, chewed, or broken before swallowing.

Question 11

What is the FDA approval status of Brigatinib?

Accepted Answer

FDA Approval History

Brigatinib received its initial FDA approval in April 2017 under the accelerated approval pathway. This original indication was for patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) who had progressed on or were intolerant to crizotinib.

In May 2020, the FDA granted full approval for brigatinib as a first-line treatment for adult patients with metastatic ALK-positive NSCLC. This expanded the drug's use to include patients who have not previously received treatment for their metastatic disease.

Regulatory Status and Availability

Biomarker Requirement: FDA-approved labeling requires the confirmation of an ALK-positive tumor status using a validated test before beginning therapy.

Generic Availability: There is currently no generic version of brigatinib available in the United States. It is only available under the brand name Alunbrig.

Safety Oversight: There are no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements for this medication.

Question 12

What should I know about Brigatinib and fda approval?

Accepted Answer

Initial FDA Approval

Brigatinib was first approved by the U.S. Food and Drug Administration (FDA) in April 2017. This initial accelerated approval was specifically for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who had previously taken crizotinib but saw their condition worsen or were unable to tolerate the medication.

Expanded Approval for First-Line Treatment

In May 2020, the FDA expanded the approved use of brigatinib. It is now indicated for the first-line treatment of adult patients with ALK-positive metastatic NSCLC. This expansion allows healthcare providers to prescribe the medication to patients who have not yet received other systemic therapies for their metastatic disease.

Regulatory Designations

The FDA granted brigatinib several special statuses during its clinical development to help bring the therapy to patients more quickly. These included:

Breakthrough Therapy: A designation intended to expedite the development and review of drugs for serious or life-threatening conditions.

Orphan Drug: A status given to drugs developed for rare diseases or conditions.

Priority Review: A designation for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.

Brigatinib

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Approval Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?